Last 7 days
18.1%
Last 30 days
18.0%
Last 90 days
6.7%
Trailing 12 Months
4.6%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-06-08 | Zinda Michael | acquired | 34,485 | 12.02 | 2,869 | evp, chief scientific officer |
2023-06-07 | Zinda Michael | sold | -77,040 | 12.03 | -6,404 | evp, chief scientific officer |
2023-06-06 | Zinda Michael | sold | -14,448 | 12.04 | -1,200 | evp, chief scientific officer |
2023-01-30 | Zinda Michael | acquired | - | - | 24,550 | evp, chief scientific officer |
2023-01-30 | Segal Lloyd Mitchell | acquired | - | - | 78,550 | president and ceo |
2023-01-30 | Forte Steve | acquired | - | - | 24,530 | evp, chief financial officer |
2023-01-30 | Koehler Maria | acquired | - | - | 26,450 | evp, chief medical officer |
2022-12-29 | Jerel Davis | acquired | - | - | 4,254 | - |
2022-12-29 | Jerel Davis | acquired | - | - | 70,678 | - |
2022-12-20 | Koehler Maria | acquired | 100,040 | 2.06238 | 48,507 | evp, chief medical officer |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | new | - | 36,000 | 36,000 | -% |
2023-09-07 | MPM ASSET MANAGEMENT LLC | unchanged | - | 1,659,550 | 23,727,100 | 11.64% |
2023-09-06 | Deep Track Capital, LP | unchanged | - | 2,018,430 | 28,858,100 | 1.34% |
2023-08-22 | CHI Advisors LLC | added | 0.03 | 2,226,890 | 31,726,600 | 9.63% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 0.65 | 13,378 | 176,220 | -% |
2023-08-16 | Nuveen Asset Management, LLC | sold off | -100 | -235,000 | - | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | added | 2.74 | 3,000 | 28,000 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | reduced | -15.57 | -69,898 | 687,890 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | reduced | -2.81 | 551 | 12,812 | -% |
2023-08-14 | CITADEL ADVISORS LLC | added | 2,122 | 2,175,730 | 2,270,760 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | deep track capital, lp | 6.50% | 2,727,606 | SC 13G/A | |
Feb 14, 2023 | biotechnology value fund l p | 10.6% | 4,443,423 | SC 13G/A | |
Feb 14, 2023 | price t rowe associates inc /md/ | 0.1% | 26,894 | SC 13G/A | |
Feb 14, 2023 | redmile group, llc | 6.4% | 2,684,396 | SC 13G/A | |
Feb 13, 2023 | chi advisors llc | 6.67% | 2,800,126 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Jan 06, 2023 | versant venture capital v, l.p. | 1.3% | 563,403 | SC 13D/A | |
Jun 13, 2022 | versant venture capital v, l.p. | 2.0% | 850,560 | SC 13D/A | |
Jun 06, 2022 | biotechnology value fund l p | 10.4% | 4,368,757 | SC 13G/A | |
Feb 14, 2022 | redmile group, llc | 6.7% | 2,789,496 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Aug 09, 2023 | 8-K | Current Report | |
Aug 09, 2023 | 10-Q | Quarterly Report |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AAPL | 2.7T | 383.9B | -3.49% | 14.63% | 28.86 | 7.12 | -0.93% | -4.89% |
MSFT | 2.4T | 211.9B | -3.06% | 31.92% | 32.56 | 11.12 | 6.88% | -0.52% |
GOOG | 1.7T | 289.5B | -1.47% | 30.51% | 27.19 | 5.72 | 4.10% | -15.36% |
AMZN | 1.3T | 538.0B | -4.72% | 10.07% | 101.87 | 2.47 | 10.73% | 12.62% |
MID-CAP | ||||||||
JBLU | 1.5B | 9.9B | -28.14% | -36.34% | 55.75 | 0.15 | 24.14% | 106.11% |
NYMT | 795.7M | 246.5M | -4.07% | -6.47% | -5.01 | 3.23 | 6.65% | -174.04% |
SMALL-CAP | ||||||||
TLRY | 1.6B | 627.1M | -7.75% | -14.29% | -1.08 | 2.51 | -0.20% | -204.67% |
PLAY | 1.5B | 2.2B | -10.06% | 7.70% | 11.01 | 0.71 | 38.20% | -10.10% |
MFA | 1.0B | 543.3M | -3.23% | 5.22% | -715.94 | 1.91 | 31.74% | 78.13% |
NKLA | 961.6M | 56.2M | -5.30% | -69.36% | -1.14 | 17.12 | 40.31% | -12.26% |
BYND | 614.9M | 356.8M | -16.65% | -37.31% | -2.19 | 1.72 | -23.03% | 15.53% |
GPRO | 507.0M | 1.0B | -15.90% | -35.94% | -19.18 | 0.49 | -11.34% | -107.10% |
CGC | 462.3M | 453.3M | 100.98% | -69.12% | -0.38 | 1.02 | -16.04% | 55.90% |
INO | 104.1M | 13.7M | -12.49% | -77.75% | -0.62 | 7.62 | 413.65% | 52.51% |
-28.3%
98.3%
97.1%
60.2%
Y-axis is the maximum loss one would have experienced if Repare Therapeutics was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Revenue | - | - | - | 131,830,000 | 90,500,667 | 49,171,333 | 7,842,000 | 7,600,000 | 964,000 | 890,000 | 664,000 | 135,000 |
Operating Expenses | 2.0% | 159,842,000 | 156,748,000 | 151,626,000 | 149,407,000 | 142,218,000 | 129,751,000 | 116,260,000 | 97,861,000 | 79,991,000 | 65,368,000 | 54,437,000 |
S&GA Expenses | 2.4% | 33,091,000 | 32,310,000 | 32,560,000 | 32,260,000 | 30,952,000 | 29,755,000 | 26,213,000 | 23,369,000 | 20,769,000 | 17,400,000 | 14,346,000 |
R&D Expenses | 1.9% | 126,751,000 | 124,438,000 | 119,066,000 | 117,147,000 | 111,266,000 | 99,996,000 | 90,047,000 | 74,492,000 | 59,222,000 | 47,968,000 | 40,091,000 |
EBITDA | 100.0% | - | -6,631,000 | -9,956,000 | - | -131,311,000 | -119,852,000 | -106,875,000 | - | - | -63,748,000 | -54,742,000 |
EBITDA Margin | 100.0% | - | -0.05 | -0.08 | - | -15.93 | -15.28 | -14.06 | - | - | -96.01 | -405 |
Interest Expenses | - | - | - | 1,966,000 | - | - | - | 240,000 | - | - | - | 216,000 |
Earnings Before Taxes | 278.3% | 18,724,000 | -10,500,000 | -13,900,000 | -25,972,000 | -133,087,000 | -121,757,000 | -108,586,000 | -96,701,000 | -78,746,000 | -63,748,000 | -54,742,000 |
EBT Margin | 100.0% | - | -0.08 | -0.11 | -0.29 | -16.15 | -15.53 | -14.29 | -100 | -88.48 | -96.01 | -405 |
Net Income | 89.4% | -3,084,000 | -29,231,000 | -29,047,000 | -25,679,000 | -132,032,000 | -120,248,000 | -106,908,000 | -93,881,000 | -76,740,000 | -62,233,000 | -53,417,000 |
Net Income Margin | 100.0% | - | -0.22 | -0.22 | -0.28 | -16.02 | -15.33 | -14.07 | -97.39 | -86.22 | -93.72 | -395 |
Free Cashflow | 100.0% | - | -2,048,000 | -280,000 | 6,734,000 | -114,255,000 | -102,980,000 | -87,486,000 | -81,251,000 | -68,731,000 | -13,573,000 | -8,321,000 |
Balance Sheet | (In Millions) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
Assets | -10.3% | 302 | 336 | 364 | 409 | 308 | 337 | 369 | 296 | 321 | 339 | 357 | 370 | 382 | 103 |
Current Assets | -10.3% | 292 | 326 | 354 | 391 | 290 | 319 | 351 | 280 | 309 | 328 | 347 | 361 | 377 | 99.00 |
Cash Equivalents | -4.9% | 116 | 121 | 160 | 155 | 276 | 305 | 334 | 261 | 294 | 312 | 326 | 348 | 370 | 95.00 |
Net PPE | -10.7% | 5.00 | 5.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 2.00 | 2.00 |
Liabilities | -34.0% | 56.00 | 85.00 | 85.00 | 103 | 83.00 | 78.00 | 80.00 | 77.00 | 76.00 | 71.00 | 70.00 | 69.00 | 68.00 | 13.00 |
Current Liabilities | -34.2% | 53.00 | 81.00 | 79.00 | 62.00 | 39.00 | 34.00 | 35.00 | 23.00 | 23.00 | 12.00 | 11.00 | 10.00 | 10.00 | 4.00 |
Shareholder's Equity | -2.3% | 245 | 251 | 280 | 306 | 226 | 259 | 288 | 218 | 245 | 268 | 287 | 301 | 314 | - |
Retained Earnings | -4.4% | -286 | -274 | -239 | -207 | -283 | -245 | -210 | -181 | -151 | -124 | -103 | -88.09 | -74.34 | -49.94 |
Additional Paid-In Capital | 14.5% | 49.00 | 43.00 | 37.00 | 32.00 | 27.00 | 23.00 | 18.00 | 14.00 | 11.00 | 8.00 | 6.00 | 5.00 | 4.00 | 4.00 |
Shares Outstanding | 0.0% | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 | 37.00 | 37.00 | 37.00 | 37.00 | 14.00 | 3.00 | 2.00 |
Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 |
Cashflow From Operations | -422.0% | -7,611 | -1,458 | 322 | 9,221 | -111,710 | -101,575 | -85,796 | -78,005 | -65,336 | -10,594 | -6,084 | -2,483 | 11,770 | -33,218 | -18,429 | -23,404 | -6,464 |
Share Based Compensation | 7.2% | 22,518 | 20,998 | 19,691 | 18,449 | 17,089 | 15,527 | 12,829 | 9,939 | 7,117 | 4,323 | 2,537 | 1,729 | 985 | 795 | 511 | 508 | 372 |
Cashflow From Investing | 16.2% | -153,208 | -182,867 | -175,778 | -210,234 | -1,693 | -501 | -1,676 | -10,525 | -10,609 | -10,505 | -9,763 | -1,259 | -967 | -1,272 | -1,304 | -724 | -760 |
Cashflow From Financing | -15.7% | 887 | 1,052 | 880 | 95,277 | 95,371 | 95,615 | 95,557 | 1,284 | -774 | 247,803 | 247,842 | 247,553 | 331,496 | 109,960 | 103,243 | 328,992 | 41,990 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Revenue: | ||||
Collaboration agreements | $ 30,249 | $ 679 | $ 35,927 | $ 1,087 |
Operating expenses: | ||||
Research and development, net of tax credits | 33,788 | 31,475 | 65,618 | 57,933 |
General and administrative | 8,719 | 7,938 | 17,248 | 16,717 |
Total operating expenses | 42,507 | 39,413 | 82,866 | 74,650 |
Loss from operations | (12,258) | (38,734) | (46,939) | (73,563) |
Other income (expense), net | ||||
Realized and unrealized (loss) gain on foreign exchange | (41) | 141 | (97) | 124 |
Interest income | 3,489 | 544 | 6,916 | 673 |
Other expense | (26) | (11) | (41) | (19) |
Total other income, net | 3,422 | 674 | 6,778 | 778 |
Loss before income taxes | (8,836) | (38,060) | (40,161) | (72,785) |
Income tax expense | (3,110) | (33) | (6,726) | (65) |
Net loss | (11,946) | (38,093) | (46,887) | (72,850) |
Unrealized (loss) gain on available-for-sale marketable securities | (189) | 0 | 4 | 0 |
Total other comprehensive (loss) gain | (189) | 0 | 4 | 0 |
Comprehensive loss | $ (12,135) | $ (38,093) | $ (46,883) | $ (72,850) |
Net loss per share attributable to common shareholders--basic | $ (0.28) | $ (0.91) | $ (1.11) | $ (1.74) |
Net loss per share attributable to common shareholders--diluted | $ (0.28) | $ (0.91) | $ (1.11) | $ (1.74) |
Weighted-average common shares outstanding-basic | 42,089,530 | 41,899,509 | 42,065,237 | 41,880,666 |
Weighted-average common shares outstanding-diluted | 42,089,530 | 41,899,509 | 42,065,237 | 41,880,666 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 115,544 | $ 159,521 |
Marketable securities | 165,148 | 184,420 |
Income tax receivable | 1,751 | 0 |
Other current receivables | 5,281 | 4,323 |
Prepaid expenses | 4,201 | 5,715 |
Total current assets | 291,925 | 353,979 |
Property and equipment, net | 4,821 | 4,228 |
Operating lease right-of-use assets | 4,434 | 5,371 |
Other assets | 408 | 497 |
TOTAL ASSETS | 301,588 | 364,075 |
CURRENT LIABILITIES: | ||
Accounts payable | 4,893 | 461 |
Accrued expenses and other current liabilities | 21,628 | 21,645 |
Operating lease liability, current portion | 2,320 | 2,171 |
Deferred revenue, current portion | 24,412 | 53,102 |
Income tax payable | 0 | 1,240 |
Total current liabilities | 53,253 | 78,619 |
Operating lease liability, net of current portion | 2,226 | 3,257 |
Deferred revenue, net of current portion | 695 | 2,682 |
TOTAL LIABILITIES | 56,174 | 84,558 |
SHAREHOLDERS’ EQUITY | ||
Preferred shares, no par value per share; unlimited shares authorized as of June 30, 2023 and December 31, 2022, respectively; 0 shares issued and outstanding as of June 30, 2023, and December 31, 2022, respectively | 0 | 0 |
Common shares, no par value per share; unlimited shares authorized as of June 30, 2023 and December 31, 2022; 42,093,946 and 42,036,193 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 482,739 | 482,032 |
Additional paid-in capital | 49,299 | 37,226 |
Accumulated other comprehensive loss | (424) | (428) |
Accumulated deficit | (286,200) | (239,313) |
Total shareholders’ equity | 245,414 | 279,517 |
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ 301,588 | $ 364,075 |